NEW YORK, Oct. 17, 2018 /PRNewswire/ -- Spherix
Incorporated (Nasdaq: SPEX) today provided shareholders with a
video demonstration on its website of the potential effectiveness
of CBM BioPharma, Inc.'s ("CBM) innovative drug
platform. As previously disclosed on October 11, 2018, Spherix entered into a merger
agreement with CBM, a privately held innovative pharmaceutical
company focused on the development of drugs in the
multibillion-dollar oncology therapeutics market. The notable
video, which was recorded at Wake Forest
University, visually demonstrates the potential
effectiveness of one of CBM's primary drug candidates known as
KPC34. Researchers at Wake Forest
have been testing whether KPC34 can be used on mouse subjects to
treat Acute Lymphoblastic Leukemia (ALL) that has spread to the
nervous system. Once recurrent ALL spreads to the nervous
system, patients often experience paralysis.
In the video, a mouse which suffers from hind leg paralysis as a
result of recurrent late staged ALL is shown to improve
dramatically from the paralysis within forty-eight hours of being
treated with KPC34. Within just twenty-four hours of the
first injection of KPC34, the mouse could walk. Forty-eight hours
later a second injection was administered and the mouse was able to
move about without challenges.
Anthony Hayes, CEO of Spherix,
stated, "This remarkable video demonstrates the tremendous
potential for this drug to treat ALL. The video was part of a
written submission on KPC34 to PLOS OneTM a peer
reviewed medical journal. We are collecting additional information
to continually provide our shareholders with updates to help better
educate them on these compounds and the biotechnology space
generally. We anticipate further updates in the future."
About Spherix
Spherix is committed to advancing innovation by active
participation in all areas of the patent market. Spherix draws on
portfolios of pioneering technology patents to partner with and
support product innovation. Spherix has acquired over 100 patents
from Rockstar Consortium Inc., and several hundred patents issued
to Harris Corporation, covering a variety of methods and components
involved in switching, routing, networking, optical and
telecommunication sectors.
About CBM BioPharma, Inc.
CBM BioPharma, Inc. (www.cbmbiopharmainc.com) is a privately
held pharmaceutical company with exclusive drug development rights
from world renowned partners like Wake Forest
University and University of
Texas at Austin. The Company has a team of leading
drug development scientists who help advance their
technology. The CBM platform focuses on the treatment of
numerous cancers, including acute myeloid leukemia (AML), Acute
Lymphoblastic Leukemia (ALL) and pancreatic cancer.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its patent business contained therein. Thus,
actual results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
Spherix:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@spherix.com
|
|
www.spherix.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/spherix-provides-video-demonstration-of-cbm-drug-reversing-paralysis-in-preclinical-study-300732544.html
SOURCE Spherix Incorporated